Financial Performance - The company's operating revenue for 2017 was ¥3,843,771,351.48, representing a 7.76% increase compared to ¥3,567,078,260.29 in 2016[6]. - The net profit attributable to shareholders for 2017 was ¥380,226,696.71, a 2.11% increase from ¥372,380,254.53 in 2016[6]. - The net profit after deducting non-recurring gains and losses was ¥366,135,795.24, up 7.48% from ¥340,668,458.99 in 2016[6]. - The total assets at the end of 2017 were ¥4,167,391,907.31, reflecting a 7.83% increase from ¥3,864,895,456.79 at the end of 2016[6]. - The net assets attributable to shareholders increased by 9.33% to ¥3,008,549,792.01 from ¥2,751,851,044.83 at the end of 2016[6]. - The basic earnings per share for 2017 was ¥0.31, a 3.33% increase from ¥0.30 in 2016[6]. - The diluted earnings per share also stood at ¥0.31, reflecting the same 3.33% increase from ¥0.30 in 2016[6]. - The weighted average return on equity decreased to 13.20% from 14.56% in 2016, a decline of 1.36%[6]. - The company reported a total of ¥1,128,756,026.65 in revenue for the fourth quarter of 2017, which was the highest quarterly revenue for the year[21]. - In 2017, the company achieved total revenue of 3.844 billion yuan, a net profit of 441 million yuan, and a net profit attributable to shareholders of 380 million yuan, representing a year-on-year growth of 2.11%[42]. Profit Distribution - The company reported a profit distribution plan of 1.00 RMB per 10 shares for all shareholders, based on a total of 1,238,340,076 shares[4]. - In 2016, the company reported a net profit of RMB 372,380,254.53 and proposed a cash dividend of RMB 1.00 per 10 shares, totaling RMB 123,834,007.60, which is 33.25% of the net profit[109]. - In 2017, the net profit attributable to the parent company was RMB 380,226,696.71, with a proposed cash dividend of RMB 1.00 per 10 shares, amounting to RMB 123,834,007.60, representing 32.57% of the net profit[111]. - The company had an undistributed profit of RMB 1,255,512,233.19 at the end of 2017, which will be carried forward to the next year[113]. - The cash dividend policy is compliant with the company's articles of association and shareholder resolutions, ensuring the protection of minority shareholders' rights[108]. - The company has consistently met the requirement of distributing at least 30% of the average distributable profit over the last three years in cash dividends[107]. Operational Challenges and Risks - The company has faced risks related to industry policy adjustments, market competition, and product pricing pressures due to government regulations[34]. - The company has not faced any significant risks that could materially impact its operations during the reporting period[4]. - The company has seen a significant increase in the number of grassroots medical institutions since the implementation of the hierarchical diagnosis and treatment system[31]. - The company faced challenges in innovation capabilities, particularly in new product development and marketing strategies, indicating a need for significant improvement[54]. Strategic Initiatives - The company aims to focus on new product development, technological advancements, and market expansion in 2018, with funding primarily sourced from internal cash flow[32]. - The company is actively exploring mergers and acquisitions as part of its strategy to expand its business operations[32]. - The company launched 28 new products in 2017 and initiated 6 projects for the consistency evaluation of generic drugs, enhancing market competitiveness[44]. - The company has established a strict quality control system and has obtained GSP and GMP certifications to mitigate drug safety risks[36]. - The company is committed to enhancing product quality standards to improve competitiveness in response to price reduction risks[35]. Research and Development - Research and development investment amounted to ¥27,349,224.40, a decrease of 1.08% compared to ¥27,647,630.73 in 2016[72]. - The number of R&D personnel decreased by 7.17% from 251 in 2016 to 233 in 2017[72]. - R&D investment as a percentage of operating income was 0.71%, down from 0.78% in 2016[72]. - The company engaged in 156 technical projects in 2017, focusing on innovation and industrial transformation[44]. Corporate Governance - The company has maintained a stable management team, with key positions held by experienced professionals in the pharmaceutical industry[173]. - The independent directors strictly fulfilled their responsibilities in accordance with relevant laws and regulations, actively participating in board meetings and safeguarding the interests of all shareholders, especially minority shareholders[196]. - The audit committee held four meetings during the reporting period, overseeing the audit process for the 2016 annual report and the quarterly reports for 2017, ensuring thorough review and compliance with regulatory requirements[198]. - The company has established an independent financial department and accounting system, ensuring separate financial management from Renhe Group[191]. Social Responsibility and Environmental Initiatives - The company continued its commitment to social responsibility through charitable donations and support for poverty alleviation initiatives[53]. - In 2017, the company donated a total of RMB 123,000, with RMB 50,000 specifically allocated for targeted poverty alleviation efforts[148]. - The company has implemented a comprehensive environmental management system, ensuring that wastewater discharge meets national standards, with COD levels at 6.99 mg/L, significantly below the limit of 188.6 mg/L[153]. - The company has focused on energy conservation and emission reduction, enhancing production technology to lower energy consumption levels[3]. Shareholder Information - The company has a total share capital of 1,238,340,076 shares, with 99.97% being unrestricted shares[159]. - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 325,299,386 shares, representing 26.27% of the total shares[162]. - The total number of ordinary shareholders at the end of the reporting period was 97,399, an increase from 96,791 at the end of the previous month[161]. - The company has not issued any new shares to strategic investors or general legal entities during the reporting period[162]. Employee Management - The total number of employees in the company is 7,197, with 6,936 from major subsidiaries and 261 from the parent company[183]. - The company emphasizes a performance-based compensation policy, aligning salaries with market standards and job responsibilities[184]. - Training programs are implemented to enhance employees' skills, particularly for sales and production staff, with a focus on pre-job training[185].

仁和药业股份有限公司 2018 年第一季度报告正文 证券代码：000650 证券简称：仁和药业 公告编号：2018-009 仁和药业股份有限公司 2018 年第一季度报告正文 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 1 仁和药业股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)肖雪峰声明：保证季度报告中财务报表的真实、准确、完整。 2 仁和药业股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 1,044,067,932.21 | 828,526,402.41 | 26.02% | | 归属于上市公司股东的净利润（元） | 106, ...

Financial Performance - Net profit attributable to shareholders increased by 4.12% to CNY 96,927,071.65 for the current period[8] - Operating revenue for the current period reached CNY 927,233,560.73, reflecting an 8.00% increase year-on-year[8] - The company reported a decrease of 4.43% in net profit attributable to shareholders year-to-date[8] - Basic earnings per share decreased by 2.25% to CNY 0.0782 for the current period[8] - The weighted average return on equity was 3.12%, down by 0.44% compared to the previous period[8] - The company reported a 56.42% decline in investment income, down to ¥9,353,858.63 from ¥21,465,618.07, mainly due to gains from the disposal of subsidiaries in the previous year[16] Assets and Liabilities - Total assets increased by 4.42% to CNY 4,035,909,566.20 compared to the end of the previous year[8] - The company's financial assets measured at fair value increased by 126.13% to ¥19,911,100 from ¥8,805,035 due to bank wealth management products not yet matured[16] - Accounts receivable rose by 110.96% to ¥553,942,373.32 from ¥262,587,264.10 as a result of a shift towards terminal cooperative customers and increased credit sales[16] - Other receivables surged by 277.60% to ¥58,553,350.99 from ¥15,506,729.60 primarily due to pre-allocated marketing promotion expenses[16] Cash Flow - The net cash flow from operating activities decreased by 18.64% to CNY 151,935,421.68 year-to-date[8] - Cash received from operating activities increased by 104.27% to ¥464,146,612 from ¥227,224,324.22, attributed to an increase in structured deposits[17] - The net cash flow from investment activities decreased by 95.97% to -¥26,045,176.43 from -¥646,812,892.15, mainly due to reduced amounts and cycles of wealth management products[17] Shareholder Information - The total number of shareholders at the end of the reporting period was 97,719[12] - The largest shareholder, Renhe (Group) Development Co., Ltd., holds 26.27% of the shares[12] Dividends and Financial Commitments - The company distributed dividends amounting to ¥147,656,621.53, a significant increase of 685.87% compared to ¥18,788,884.11 in the same period last year[17] - The company plans to ensure independent operations and avoid competition with its controlling shareholder, maintaining a commitment to transparency in related transactions[20] - The company has committed to not utilizing its controlling position to seek preferential treatment in business cooperation with related parties[20] - The company has implemented measures to ensure timely and full payment of funds in accordance with sales and procurement contracts[20] Corporate Governance and Social Responsibility - The company did not engage in any non-operational fund occupation by controlling shareholders or related parties during the reporting period[26] - In the first half of 2017, the company donated a total of RMB 123,000, including RMB 50,000 for targeted poverty alleviation[27] - The company has not conducted any targeted poverty alleviation work in the third quarter of 2017 and has no subsequent plans[27] Miscellaneous - There were no derivative investments during the reporting period[23] - There were no violations related to external guarantees during the reporting period[25] - The company’s total securities investment at the end of the reporting period was RMB 502,909,000[21] - The company did not provide any updates on new product or technology development, market expansion, or mergers and acquisitions in the extracted content[21] - The company held multiple phone communications with individuals regarding its basic production and operation status in July and September 2017[24]

仁和药业股份有限公司 2017 年半年度报告全文 仁和药业股份有限公司 2017 年半年度报告 2017-022 2017 年 08 月 1 仁和药业股份有限公司 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)肖雪峰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本半年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资 者的实质承诺，敬请投资者注意风险。 《证券日报》《证券时报》《中国证券报》和巨潮资讯网 www.cninfo.com.cn 为本公司 2017 年半年度报告选定的信息披露媒体，本公司所有信息均以在上述 选定媒体刊登的信息为准。同时，报告期内，不存在对公司生产经营产生实质 性影响的特别重大风险，请查阅第四节公司经营情况讨论与分析中第十小点"公 司面临的风险和应对措施",敬请投资者注意风险。 公司计划不派 ...

Financial Performance - The company's revenue for Q1 2017 was ¥828,526,402.41, a decrease of 1.18% compared to ¥838,381,744.70 in the same period last year[8] - Net profit attributable to shareholders was ¥79,376,486.57, down 23.61% from ¥103,915,590.78 year-on-year[8] - Basic earnings per share decreased to ¥0.0641, down 23.60% from ¥0.0839 in the same period last year[8] - The weighted average return on equity was 2.84%, down from 4.26% in the same period last year, a decrease of 1.42%[8] - The company anticipates significant changes in net profit compared to the same period last year, indicating potential losses[21] Cash Flow and Assets - The net cash flow from operating activities was negative at ¥138,538,473.11, a decline of 293.24% compared to ¥71,691,631.75 in the previous year[8] - Cash and cash equivalents decreased by 32.04% to ¥708,922,525.88 due to the purchase of bank wealth management products[17] - Accounts receivable increased by 69.46% to ¥444,990,415.65 as a result of a shift to credit sales with terminal cooperative customers[17] - Other receivables surged by 301.96% to ¥62,331,230.61 primarily due to pre-allocated marketing promotion expenses[17] - Cash received from investment decreased by 33.33% to ¥1,390,207,058.37, reflecting a reduction in wealth management funds[18] - Cash flow from financing activities fell by 93.38% to ¥500,000.00, as last year's figures included substantial funds from a new company establishment[18] - Total assets at the end of the reporting period were ¥3,828,507,190.94, a decrease of 0.94% from ¥3,864,895,456.79 at the end of the previous year[8] - Net assets attributable to shareholders increased by 2.88% to ¥2,831,228,192.44 from ¥2,751,851,044.83 at the end of the previous year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 101,852[12] - The largest shareholder, Renhe (Group) Development Co., Ltd., held 26.27% of the shares, totaling 325,299,386 shares[12] Investments - The company holds a total of 1,450,000 shares in various stocks, with a total value of 10,549,220 yuan at the end of the reporting period[22] - The largest single investment is in Qibin Group, holding 990,000 shares, which represents 68.28% of the total shares held[22] - The company reported a loss of 13,399.70 yuan during the reporting period[22] - There were no derivative investments during the reporting period[23] Compliance and Governance - The company has committed to maintaining independence in operations, assets, and finances to avoid conflicts of interest with major shareholders[20] - The company did not engage in any non-compliance external guarantees during the reporting period[26] - There were no non-operating fund occupations by controlling shareholders or their affiliates during the reporting period[27] - The company conducted multiple phone communications regarding major shareholder reductions, but no written materials were provided[25] Strategic Plans - The company plans to implement new strategies for market expansion and product development in the upcoming quarters[19] - The company reported non-recurring gains and losses totaling ¥927,177.86 for the period[9] - Financial expenses decreased significantly by 479.23% to -¥2,178,742.03, attributed to increased interest income from larger cash deposits[17]

仁和药业股份有限公司 2016 年年度报告全文 仁和药业股份有限公司 本年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺，敬请投资者注意风险。 《证券日报》、《证券时报》、《中国证券报》和巨潮资讯网 www.cninfo.com.cn 为本公司 2016 年度选定的信息披露媒体，本公司所有信息均以在上述选定媒体 刊登的信息为准。同时，报告期内，不存在对公司生产经营产生实质性影响的 特别重大风险。公司已在本报告中阐述公司在生产经营过程中可能面临的各种 风险，请查阅第三节公司业务概要中"可能面对的风险",敬请投资者注意风险。 所有董事均已出席了审议本报告的董事会会议。 2016 年年度报告 2017-010 2017 年 04 月 1 仁和药业股份有限公司 2016 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)肖雪锋声明：保证年度报告中财务报告的真实、准确、完整 ...

仁和药业股份有限公司 2016 年第三季度报告正文 证券代码：000650 证券简称：仁和药业 公告编号：2016-065 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)陈远青声明：保证季度报告中财务报表的真实、准确、完整。 2 仁和药业股份有限公司 2016 年第三季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 仁和药业股份有限公司 2016 年第三季度报告正文 1 仁和药业股份有限公司 2016 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 3,675,796,931.51 | 3,156,270,749.52 | | 16 ...

仁和药业股份有限公司 2016 年半年度报告全文 仁和药业股份有限公司 2016 年半年度报告 2016-045 2016 年 08 月 1 仁和药业股份有限公司 2016 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介 6 | | 第三节 会计数据和财务指标摘要 8 | | 第四节 董事会报告 10 | | 第五节 重要事项 20 | | 第六节 股份变动及股东情况 27 | | 第七节 优先股相关情况 31 | | 第八节 董事、监事、高级管理人员情况 32 | | 第九节 财务报告 33 | | 第十节 备查文件目录 128 | 仁和药业股份有限公司 2016 年半年度报告全文 释义 | | 释义项 | 指 | 释义内容 | | --- | --- | --- | --- | | | 中国证监会、证监会 | 指 | 中国证券监督管理委员会 | | | 江西证监局 | 指 ...

仁和药业股份有限公司 2016 年第一季度报告正文 证券代码：000650 证券简称：仁和药业 公告编号：2016-026 仁和药业股份有限公司 2016 年第一季度报告正文 1 仁和药业股份有限公司 2016 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)陈远青声明：保证季度报告中财务报表的真实、准确、完整。 2 仁和药业股份有限公司 2016 年第一季度报告正文 第二节 主要财务数据及股东变化 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 838,381,744.70 | 504,107,600.10 | 66.31% | | 归属于上市公 ...

仁和药业股份有限公司 2015 年年度报告全文 仁和药业股份有限公司 2015 年年度报告 2016-025 2016 年 04 月 1 仁和药业股份有限公司 2015 年年度报告全文 第一节 重要提示、目录和释义 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人梅强、主管会计工作负责人彭秋林及会计机构负责人(会计主管 人员)陈远青声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺，敬请投资者注意风险。 《证券日报》、《证券时报》、《中国证券报》和巨潮资讯网 www.cninfo.com.cn 为本公司 2015 年度选定的信息披露媒体，本公司所有信息均以在上述选定媒 体刊登的信息为准。同时，本年度报告涉及的未来计划、发展战略等前瞻性描 述不构成公司对投资者的实质承诺，敬请投资者注意风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | --- | ...